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Objectives: The procedure for setting clinical breakpoints (CBPs) for antimicrobial susceptibility has been poorly
standardizedwith respect to population data, pharmacokinetic parameters and clinical outcome. Tools to stand-
ardize CBP setting could result in improved antibiogram forecast probabilities. We propose a model to estimate
probabilities for methodological categorization errors and defined zones of methodological uncertainty (ZMUs),
i.e. ranges of zone diameters that cannot reliably be classified. The impact of ZMUs onmethodological error rates
was used for CBP optimization.
Methods: The model distinguishes theoretical true inhibition zone diameters from observed diameters, which
suffer from methodological variation. True diameter distributions are described with a normal mixture model.
Themodel was fitted to observed inhibition zone diameters of clinical Escherichia coli strains. Repeatedmeasure-
ments for a quality control strain were used to quantifymethodological variation.
Results: For 9 of 13 antibiotics analysed, our model predicted error rates of,0.1% applying current EUCAST
CBPs. Error rates were .0.1% for ampicillin, cefoxitin, cefuroxime and amoxicillin/clavulanic acid. Increasing the
susceptible CBP (cefoxitin) and introducing ZMUs (ampicillin, cefuroxime, amoxicillin/clavulanic acid) decreased
error rates to,0.1%. ZMUs contained low numbers of isolates for ampicillin and cefuroxime (3% and 6%),
whereas the ZMU for amoxicillin/clavulanic acid contained 41% of all isolates andwas considered not practical.
Conclusions:We demonstrate that CBPs can be improved and standardized by minimizing methodological cat-
egorization error rates. ZMUs may be introduced if an intermediate zone is not appropriate for pharmacokinetic/
pharmacodynamic or drug dosing reasons. Optimized CBPs will provide a standardized antibiotic susceptibility
testing interpretation at a defined level of probability.
Introduction
Antibiotic susceptibility testing (AST) results are used by clinicians
as a guide to select themost appropriate drugs in the treatment of
patients suffering from infectious diseases. In general, the labora-
tory does not provide raw data on AST, such as inhibition zone
diameters, but the results are categorized using clinical break-
points (CBPs) according to the expected clinical outcome.1,2
Although this approach is helpful in daily clinical practice, it leads
to amajor loss of information.
CBP settinghas traditionally beena poorly standardized proced-
ure: susceptibility data on pathogens, pharmacodynamic/
pharmacokinetic values and clinical outcome studies are taken
into account, but a set of rules thatwouldmake CBP categorization
reliable has not yet been established.1,3 In contrast, in clinical
chemistry raw results are transmitted to clinicians together with
reference ranges for normal values for the patient’s population,
allowing clinicians to adequately judge the deviation of the meas-
ured value from the reference cut-off.4
Clinical categories in AST that are currently delineated by CBPs
are ‘susceptible’, which is associated with clinical success, ‘resist-
ant’, which predicts clinical failure, and ‘intermediate’, which is
used in an ambiguous way. Originally, the EUCAST definition con-
tained two aspects of the intermediate category, i.e. it ‘implied
that an infection due to the isolatemay be appropriately treated in
body sites where the drugs are physiologically concentrated or
when a high dosage of drug can be used’ and ‘it also indicated a
buffer zone that should prevent small, uncontrolled, technical fac-
tors from causing major discrepancies in interpretations.’5 The
use of a dual definition for the intermediate category resulted in
confusion and hampered understanding of the primary purpose
of AST reports, i.e. allowing clinicians to select the most
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appropriate drug for antimicrobial therapy. EUCAST recently pro-
posed a re-definition of the intermediate category, removing the
concept of a technical buffer zone.5 The intermediate category is
now suggested to be defined as ‘a level of antimicrobial activity
associated with a high likelihood of therapeutic success but only
when a higher dosage of the agent than normal can be used or
when the agent is physiologically concentrated at the site of infec-
tion.’ However, themethodological variation of AST remains and is
no longer addressed by intermediate categorization, nor is it indi-
cated on AST reports. Therefore, major erroneous forecasts of
therapeutic outcome success are likely.6–8
Tools that optimize and harmonize CBPs by reducing error
rates seem beneficial for antibiogram reliability andmay provide
the basis for standardizing the process of CBP setting.9 If accept-
able categorization error rates cannot be achieved by adapting
CBPs, the implementation of zones of methodological uncer-
tainty (ZMUs) may be helpful to indicate less reliable measure-
ments, avoiding the term ‘intermediate’ and the associated
confusion.8
In this study we present a mathematical tool to calculate the
rates ofmisclassifications as far as they are due tomethodological
variation. This tool, named MASTER (Model for AST Error Rates),
takes into account technical variation, aswell as biological and epi-
demiological factors. It is therefore suitable for studying the effect
of CBP changesand/or introduction of ZMUs in individual epidemio-
logical settings and in aggregated datasets. For proof of principle
we applied MASTER to systematically evaluate the current CBPs
issued by EUCAST using a broad set of inhibition zone diameters of
non-duplicate, non-outbreak clinical Escherichia coli strains origi-
nating fromour clinical laboratory.
Methods
Model for true and observed inhibition zone diameters
We developed MASTER to determine the methodological error for categor-
ization of Kirby–Bauer inhibition zone diameters. MASTER distinguishes be-
tween the experimentally observed inhibition zone diameter Y, which
suffers frommethodological variation, and the theoretical true diameter X,
which is not observed. The relationship between X and Y is given by
Y ¼ X þ E, where Emodels themethodological variation.
We modelled the distribution of the true diameter X as a mixture of
n2 components with weightswi satisfying wi0 and
Pn
i¼1 wi ¼ 1. The
true diameter is 6mm for the first component, which therefore captures
all the strains whose growth is not affected by the antibiotic. For the
other components the true diameter is normally distributed with mean
li and variance r
2
i . The cumulative distribution function of X thus has the
form:









where H is the Heaviside step function and F is the cumulative distribution
function of the standard normal distribution.
The true diameter X is unknown, and we observe Y ¼ X þ E instead.
Our model for the methodological variation E depends on the compo-
nent. The variation associated with the first component is assumed to
be zero. For the other components we assume E to be normally distrib-
uted (Figures S1 and S2, available as Supplementary data at JAC Online)
and independent of X with zero mean and variance r2E (Figure S3 and
Table S1).
Under these assumptions regarding X and E the cumulative distribution
function of Y is given by:


















Note that we do not account for the fact that the observed diameters are
typically rounded to integer values.
Probabilities of methodological misclassification errors
Misclassification errors are traditionally split according to their therapeutic
implications. Erroneous categorizations of true-susceptible isolates as re-
sistant are referred to asmajor errors (MEs) and lead to unnecessary restric-
tion of therapeutic options. The most serious clinical implications result
from very major errors (VMEs), i.e. categorizations of true-resistant isolates
as susceptible, as there is a high likelihood of therapeutic failure. Minor
errors (mEs), i.e. misclassifications of true-intermediate isolates as resistant
or as susceptible or of true-resistant or true-susceptible isolates as inter-
mediate, have limited therapeutic consequences.10 Based on a pair of
CBPs zSzR>6mm, strains are defined to be resistant if the true diameter
satisfies x<zR, intermediate if zRx<zS and susceptible if zSx. However,
the prediction is based on the observed diameter Y, which due to themeth-
odological variation E inevitably results inmisclassification errors. The prob-
ability that a very major methodological misclassification error occurs is,
based onMASTER:





g x; yð Þdydx;
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and u ; l; r2
 
is the density function of a normally distributed random
variable with mean l and variance r2. Similarly, the probability of a major
methodologicalmisclassification error is:





g x; yð Þdydx
and the probability of aminormethodologicalmisclassification error is:
pmE ¼ pðX<zR and zRY<zSÞ þ pðzRX<zS and Y<zRÞ






























In the present studyweused the CBPs issued by EUCAST throughout.11
Forecast probabilities
Given an observed diameter y, what is the probability that no ME or VME
occurred? This probability, which is a function of y, is the quantity of
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principal interest in the present work. Under the model developed above,
the probability of a very major methodological misclassification error given
y is:
pVME yð Þ ¼
0; if y<zS;
p X<zRjY ¼ yð Þ ¼
Ð zR
1 g x; yð Þdx














I yð Þ ¼
1; if y ¼ 0;
0; else:
(
Similarly, the probability of a major methodological misclassification error
given y is:
pME yð Þ ¼
p XzSjY ¼ yð Þ ¼
Ð1
zS
g x; yð Þdx
w1I y  6mmð Þ þ
Pn













The forecast probability, i.e. the probability given y that no major or very
major misclassification error occurs due to methodological variation, is
then simply:
pf yð Þ ¼ 1 pVME yð Þ  pME yð Þ:
ZMU
We can identify inhibition zone diameters for which the AST categorization
is ambiguous due to methodological variation based on the forecast
probabilities pf yð Þ. In particular, we define the ZMU to encompass the
observeddiameters that satisfy pf yð Þ<0:99 or zRy<zS. The ZMUcontains
all the observed diameters for which the risk of an ME or VME is .1% or
which are in the intermediate zone.
Clinical isolates
Antimicrobial susceptibility data on non-duplicate, non-outbreak clinical
E. coli strains were used in this study. Clinical isolates included were col-
lected over a 5year period from2010 to 2014 in the clinicalmicrobiology la-
boratory of the Institute of Medical Microbiology, University of Zurich. The
majority of the isolates were isolated from specimens of the University
Hospital of Zurich, an 850bed tertiary care hospital.
AST
AST was performed by the disc diffusion method following EUCAST stand-
ard procedures12 on Mueller–Hinton II agar (Becton-Dickinson, Franklin
Lakes, NJ, USA), and with antibiotic discs from i2a (Montpellier, France).
Inhibition zone diameters were automatically recorded using the Sirscan/
Sirweb system (i2a).13 The automated zone reader had been previously
calibrated using EUCAST quality control (QC) strains and tables, and all tech-
nical settings had been parameterized to meet EUCAST QC target and
range requirements. Furthermore, calibration to EUCAST QC requirements
was assured by running weekly QC strains. In addition, isolates with inhib-
ition zone sizes in the left tail area (i.e. a range of 4mm starting at the left
end) of the distribution curves were verified by visual inspection of plate
images. Adjustments, if necessary, were done on-screen, and the adjusted
result was used in the analysis. Isolates were eliminated from the data set
if errors were found [e.g. contaminated plates, false identification,
technically failed measurements of inhibition zones (i.e. the software was
clearly not measuring the zone of inhibition as the digital calliper was visu-
ally distant from the zone edge), incompatibility with WT definition within
an antibiotic class (i.e. if the expected susceptibility pattern for a given WT
was inconsistent, e.g. norfloxacin susceptible, levofloxacin resistant)].
Isolates were considered as duplicates and excluded from the analysis if
they originated from the same patient and showed at most onemajor and
twominor differences in AST interpretation.14 Table 1 lists the antibiotics for
which ASTwas performed and CBPs were available. Our data set comprised
inhibition zone diameters from 9766 strains for b-lactams, from 9761
strains for quinolones, from 3521 strains for aminoglycosides and from
1089 strains for tigecycline.
Model fitting
Wefitted ourmodel tomeasured inhibition zone diameters as follows. First,
we estimated r2E (the variance of the methodological variation) based on
55 independent repeated measurements of inhibition zone diameters for
the QC strain E. coli ATCC 25922 using different lots of antibiotic discs and
different lots of Mueller–Hinton agar plates from the same manufacturer.
Experiments were performed and read by different experienced persons on
different days to ensure that the variation closely resembled routine condi-
tions in the clinical laboratory.
Second, we used AST data to fit the parameters describing the distribu-
tion of the observed diameter Y. In particular, we estimatedw1 as the frac-
tion of data points in the sample that are equal to 6mm. The parameters of




E , were esti-
mated by fitting a normal mixture model of n 1 components to the data
with observed diameters .6mm using the expectation-maximization al-
gorithm.15 Models were generated for n ¼ 2; . . . ; 10, and the best one
was selected based on the Bayesian information criterion16,17 after exclud-
ingmodels that did not satisfy ri>0, i.e.models that hada componentwith
variance below r2E . Our data set did not contain any strains with diameters
below the CBP defining resistance for imipenem and tigecycline. We thus
refrained fromapplying ourmodel to these twoantibiotics.
We used quantile–quantile (Q–Q) plots to compare the empirical distri-
bution of inhibition zone diameters with the fit from our model.18 Briefly,
Q–Q plots compare the quantiles of two distributions and are thus a graph-
ical means of assessing similarity between them. If two distributions agree
perfectly, their quantiles coincide and the plotted points lie on the identity
line.
Software
All computations were performed with the free software R, version 3.2.3.19
Normalmixturemodelswere fittedusing theRpackagemclust, version5.2.20
Results
Model fitting
Repeated measurements of inhibition zone diameters for the
QC strain E. coli ATCC 25922 were approximately normally distrib-
uted (Figures S1 and S2) and were in agreement with the target
ranges published by EUCAST.21 Standard deviations for E. coli ATCC
25922 ranged from1.2 to 2.0mm(Table 1). Comparisonwith clinical
strains suggested modelling the methodological variation as ap-
proximately constant for diameters.6mm(Figure S3 and Table S1).
Figure 1 visualizes our model. The Q–Q plots showed that
MASTER described the empirical distributions well. Themodel cap-
tured accumulation of diameters of 6mm and was sufficiently
complex to capture non-normal distributions for WT strains
(e.g. cefotaxime, Figure 1f). Differences between fitted model and
Categorization errors of antimicrobial susceptibility testing JAC
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experimental dataweremost pronounced for large inhibition zone
diameters (Figure 1). For cefotaxime, cefoxitin, ceftriaxone and
amoxicillin/clavulanic acid, the Q–Q plots also highlighted discrep-
ancies for low inhibition zones despite the fact that the mixture
model had a separate component for diameters of 6mm. TheQ–Q
plots indicate that the distributions of diameterswere difficult to fit
for ertapenem, meropenem and gentamicin (Figures 1j, k and l).
For ertapenem and meropenem, this reflects the small number of
strainswith observeddiameters below the CBPs defining resistance
(53 and 3 strains out of 9766 for ertapenem and meropenem, re-
spectively). The observed lack of fit disappeared if the clinical data
were extended by 200 simulated resistant isolates (Figure S4). For
gentamicin, themain peak of the distribution (centred at 22.5mm,
i.e. the part of the distribution encompassing the WT strains)
seemed too heavy-tailed to be describedby a normal distribution.
Forecast probabilities and ZMUs
The forecast probability, i.e. the probability that no MEs or VMEs
occurs due to methodological variation, is shown in Figure 1. We
emphasized that the forecast probability, as defined here, is a
function of the observed diameter, i.e. it reflects how far a specific
measurement is from the CBPs. Indeed, the forecast probability
was 1 within the intermediate zone and for observed diameters
sufficiently distant from the CBPs. However, the forecast probabil-
ity was ,1 in the immediate vicinity of the intermediate zone or
close to the CBP in settings without an intermediate zone
(ampicillin, cefoxitin, amoxicillin/clavulanic acid and cefuroxime). A
forecast probability different from 1 can lead to major or very
majormisclassification errors.
Weuse the termZMU for the diameters in the intermediate zone
or with a forecast probability ,0.99. The median width of the ZMU
was 4.5mm. For antibiotics without an intermediate zone defined
by EUCAST, the width of the ZMU varied between 5 and 7mm
(Table 1).11 The ZMU coincided with the intermediate zone for erta-
penem, gentamicin and tobramycin. For the remaining antibiotics,
the ZMU extended the intermediate zone by 1 or 2mm. MASTER
predicted that ,5% of all strains have observed diameters within
the ZMU formost antibiotics. The exceptionswere amoxicillin/clavu-
lanic acid (41%), cefoxitin (6%) and piperacillin/tazobactam (5%).
Rates of methodological misclassification errors
MASTER predicted ME and VME rates ,0.1% for 9 out of the
13 drugs analysed, based on current EUCAST CBPs for most antibi-
otics (Table 2). Ampicillin, cefoxitin and cefuroxime had ME and
VME rates between 0.1% and 1%, and amoxicillin/clavulanic acid
hadME and VME rates.1%. Of note, the CBP for amoxicillin/clavu-
lanic acid is located within the admissible EUCAST range for QC
strain E. coli ATCC 25922, which is considered a typical representa-
tive of the species (Figure S1). ThemE rates were between 1% and
3% for piperacillin/tazobactam, ceftazidime, cefepime and tobra-
mycin. The remaining drugs hadmE rates between 0%and 1%.
Table 1. Estimated standard deviation of the methodological variation derived from repeated measurements for the QC strain E. coli ATCC 25922,
number of components in the mixture model, Kolmogorov–Smirnov (K–S) distance between observed distribution of inhibition zone diameters and fit-
ted distribution, official CBPs (EUCAST)11 and ZMUs derived from MASTER
CBP (mm) ZMUa
Antibiotic rE (mm) Components (n) K–S distance R S min (mm) max (mm) width (mm) weight (%)
Ampicillin 1.4 6 0.03 14 14 11 16 5 3
Cefoxitin 1.4 3 0.08 19 19 15 21 6 6
Amoxicillin/clavulanic acid 1.5 3 0.06 19 19 15 22 7 41
Piperacillin/tazobactam 1.3 4 0.07 17 20 16 20 4 5
Cefuroxime 1.4 3 0.07 18 18 14 20 6 4
Cefotaxime 1.5 5 0.06 17 20 17 21 4 1
Ceftazidime 1.4 4 0.06 19 22 18 22 4 2
Ceftriaxone 1.8 3 0.07 20 23 19 23 4 1
Cefepime 1.5 5 0.06 21 24 20 24 4 2
Ertapenem 1.2 6 0.05 22 25 22 25 3 1
Imipenemb 1.3 – – 16 22 – – – –
Meropenem 1.5 4 0.06 16 22 15 22 7 0
Gentamicin 1.2 3 0.14 14 17 14 17 3 1
Tobramycin 1.4 3 0.11 14 17 14 17 3 2
Norfloxacin 1.9 4 0.04 19 22 17 22 5 1
Ciprofloxacin 2 3 0.07 19 22 18 23 5 1
Levofloxacin 1.9 5 0.03 19 22 17 22 5 2
Tigecyclineb 1.2 – – 15 18 – – – –
R, resistant (i.e. a high likelihood of therapeutic failure); S, susceptible (i.e. a high likelihood of therapeutic success).
aWe set min and max such that the ZMU is y : miny<maxf }. If the ZMU coincides with the intermediate zone, min and max are equal to the CBPs.
The weight of the ZMU is defined as the proportion of strains with observed diameters in the ZMU.
bThe data set does not contain any strains with diameters below the CBP defining resistance for imipenem and tigecycline. We thus refrained from
applying MASTER to these two antibiotics.
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ZMUs reducedME and VME rates to,0.01% for all drugs (Table 2),
and led tomE rates.1% for the drugswithout an intermediate zone
defined by EUCAST (ampicillin, cefoxitin, amoxicillin/clavulanic acid
and cefuroxime). For the remaining drugs, mE rates did not change
or increased by a factor of at most 2. The mE rate was highest for
amoxicillin/clavulanic acid (20%).
Increasing the CBPs defining resistance by 2mm reducedME and
VME rates for all drugs (Table 2). For cefoxitin, amoxicillin/clavulanic
acid and cefuroxime the ME or VME rates remained .0.1%. The mE
rates were .1% for drugs without an intermediate zone. For the re-
maining drugs, mE rates increased by a factor of at most 5. The mE
ratewashighest for amoxicillin/clavulanic acid (20%).
Ampicillin(a) (b) (c) (d)
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Figure 1. Empirical (histogram) and fitted (black line) distributions for the observed inhibition zone diameters (top), Q–Q plots with identity lines in
grey (middle) and forecast probabilities and ZMUs in grey (bottom). CBPs by EUCAST are indicated with dashed lines.11
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Discussion
In a first step we developed a mathematical model, called
MASTER, that estimates the probability that a strain is truly suscep-
tible or resistant given an observed inhibition zone diameter.
MASTER is based on two assumptions. First, the model assumes
that the observed diameter is the sum of a true, unknown diam-
eter and normally distributed methodological variation. A similar
assumption has beenmade for inhibition zone diameters22–24 and
for log-transformedMICmeasurements.25,26 The assumption that
the magnitude of the methodological variation is constant for
diameters .6mm is a common approximation, justified in our
Cefepime(i) (j) (k) (l)
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study by data from repeatedmeasurements for E. coli ATCC 25922
and 10 clinical strains (Figure S3 and Table S1). Second, we mod-
elled diameter distributions as mixtures of normal distributions,
following an established approach. Inhibition zone diameters of
WT isolates are usually modelled as normally distributed, e.g. in
the context of setting epidemiological cut-off values.1,27,28 In add-
ition, several models based on mixtures of normally distributed
components have been suggested to describe the full distribution
of log-transformedMICmeasurements.22,26,29,30
The estimated forecast probability comprises technical vari-
ation, i.e. how distant a specific diameter is from the CBP, epi-
demiological factors and unspecific biological factors such as
genetic variations or metabolic state. MASTER can be used to de-
rive forecast probabilities complementing AST categorizationswith
a quantitative measure of uncertainty to guide clinical decisions.
To test the applicability of MASTER for CBP optimization we used a
large set of inhibition zone diameters of 13 antibiotic drugs
(n"120698) originating from up to 9766 non-duplicate, non-
outbreak clinical E. coli strains that had been isolated in our clinical
laboratory from2010 to 2014.
The Q–Q plots (Figure 1) illustrate that the discrepancies be-
tween the fitted models and the data were most pronounced for
large inhibition zone diameters and in some cases for diameters of
6mm. These discrepancies are negligible as they pertained to in-
hibition zone diameters that were much larger or much smaller
than the CBPs. The discrepancies were most likely the inherent
consequence of an experimental setting that places lower and
upper bounds of 6 and 40mm, respectively, on the reported diam-
eters. In addition, the Q–Q plots showed that a sufficient amount
of data from resistant strains is required for robust modelling
by MASTER. For our particular epidemiological situation, this re-
quirement was not met for ertapenem andmeropenem (Figure 1j
and k).
The calculated forecast probabilities were used to define ZMUs.
The ZMUs encompassed ,5% of all strains for most of the antibi-
otics investigated in this study. However, the ZMUs of amoxicillin/
clavulanic acid and cefoxitin contained 41% and 6% of all strains,
respectively (Table 1 and Figure 2). This finding is particularly im-
portant given that methodological variation is no longer covered
by the proposed modification in the definition of the intermediate
zone by EUCAST.31
The error rates predicted by MASTER can lead to several prac-
tical consequences: (i) CBPs that have been derived from aggre-
gated datasets can be checked for error rates in a particular
epidemiological setting; (ii) the model can provide a rationale to
decide whether actions should be taken on CBPs to ensure optimal
forecast probabilities for therapeutic success, and/or general CBPs
may even be individually adjusted for specific epidemiological set-
tings; and (iii) MASTER can be used to calculate the effect of CBP
changes and/or the implementation of ZMUs onME/VME rates and
provides a rationale to decide whether action should be taken to
ensure optimal forecast probabilities for therapeutic success, and if
sowhat action should be taken.
To optimize CBPs for acceptable ME/vME rates, we applied a set
of three rules as triggers for action:
1. ME and VME rates of,1% are mandatory; ME and VME rates
of,0.1% are preferable.
2. (a) Increasing the susceptible CBP or implementation of a ZMU
is recommended if these actions decrease ME and/or VME
Table 2. Impact of ZMUs and increased CBPs defining susceptibility on rates of methodological misclassification errors














Ampicillin 2E#1 9E#5 2E#2 4E#1 7E#5 6E#2 0 2E!0 2E!0 introduce ZMUb
Cefoxitin 4E#1 1E#6 4E#2 7E#1 7E#6 1E#1 0 3E!0 4E!0 increase CBPsc
Amoxicillin/clavulanic acid 2E!0 1E#6 3E#1 4E!0 6E#6 7E#1 0 2E!1 2E!1 do not testd
Piperacillin/tazobactam 3E#3 2E#4 1E#5 1E#2 9E#4 1E#4 3E!0 3E!0 8E!0 –
Cefuroxime 3E#1 6E#7 3E#2 5E#1 5E#6 1E#1 0 3E!0 3E!0 introduce ZMUb
Cefotaxime 6E#3 8E#4 8E#5 2E#3 2E#4 2E#5 7E#1 7E#1 8E-1 –
Ceftazidime 3E#3 5E#4 3E#5 1E#2 1E#3 3E#4 2E!0 2E!0 6E!0 –
Ceftriaxone 2E#3 9E#4 6E#5 3E#3 5E#4 9E#4 2E#1 3E#1 1E!0 –
Cefepime 8E#3 1E#3 1E#4 8E#3 1E#3 4E#4 1E!0 2E!0 3E!0 –
Tobramycin 9E#3 9E#3 7E#5 1E#3 1E#3 2E#4 2E!0 2E!0 7E!0 –
Norfloxacin 1E#3 3E#4 7E#5 2E#2 9E#4 3E#3 6E#1 8E#1 2E!0 –
Ciprofloxacin 5E#3 6E#4 3E#4 1E#2 1E#3 2E#3 4E#1 7E#1 1E!0 –
Levofloxacin 2E#3 5E#4 1E#4 3E#2 1E#3 4E#3 9E#1 1E!0 2E!0 –
aAgreement between model and empirical distribution was poor for ertapenem, meropenem and gentamicin (Q–Q plots in Figure 1j, k and l).
Calculating error rates for these antibiotics was thus not possible.
bIntroducing a ZMU lowered ME and VME rates more than increasing the CBP defining susceptibility. The ZMU contained ,5% of all isolates (Table 1),
and mE rates were ,5%.
cCefoxitin is used as a screening drug for AmpC b-lactamases. While a ZMU would have decreased ME and VME rates by more than five orders of mag-
nitude, it is unclear what benefit a ZMU would have for a screening drug.
dIncreasing the CBP defining susceptibility resulted in ME and VME rates .0.1% and in an mE rate of 20%. The ZMU reduced ME and VME by several
orders of magnitude. However, it contained 41% of all isolates (Table 1) and entailed anmE rate of 20%.
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rates by at least one order of magnitude. (b) ZMUs must not
contain .10% of the isolates.
3. If neither increasing the susceptible CBP nor implementation
of the ZMU results in ME and VME rates of at most ,1% or if
the ZMU contained .10% of the isolates, testing of the drug is
of limited value for a given epidemiology.
For our epidemiological setting, ampicillin (10mg disc), cefoxitin,
amoxicillin/clavulanic acid and cefuroxime had ME and VME rates
.0.1%, indicating the need for action according to rule 1 (Table 2).
For these drugs, implementation of ZMUs decreased error rates to
a greater extent than increasing susceptible CBPs (Table 2) and
ZMUs would thus be recommended, applying rule 2(a). Cefoxitin,
however, is used as a screening parameter for the presence of
AmpC b-lactamases to ensure maximum sensitivity, but is not re-
ported to clinicians for therapeutic purposes.32,33 Although a ZMU
for cefoxitin would decrease ME and VME rates by more than five
orders of magnitude, it would provide no benefit for a screening
drug that is used for diagnostic purposes only. For amoxicillin/clav-
ulanic acid, the ZMU contained 41% of all isolates (Table 1) and
would thus not be practically useful (rule 2b). Furthermore, an
amoxicillin/clavulanic acid ZMU would lead to mE rates of 20%
(Table 2). Since ME and VME ,0.1% could also not be achieved by
an increased susceptible CBP for amoxicillin/clavulanic acid, report-
ing of the drug may be of limited clinical value, at least in an epi-
demiological setting like that of this study, in which many isolates
were situated close to the CBP (rule 3). Since prediction of thera-
peutic success is frequently uncertain, amoxicillin/clavulanic acid
may no longer be recommended for clinical use in E. coli. Ampicillin
and cefuroxime are reported for treatment purposes, and ,5% of
the isolates were contained in their respective ZMUs (Table 1).
Therefore, the implementation of ZMUs for ampicillin and cefurox-
ime can be recommended.
By design, this study is limited to the analysis of the epidemi-
ology of a single geographical location. However, MASTER can
readily be applied to other regional epidemiologies to evaluate
local adjustments of CBPs, or it could be applied to aggregated
datasets, e.g. those used by EUCAST and CLSI to set CBPs.
If aggregated data are analysed, EUCAST or CLSI QC ranges can
be used as a surrogate for methodological variation since they
are based on aggregated data using disc/agar plates from differ-
ent manufacturers.21 Bootstrapping can be used to quantify the
uncertainty of ZMUs and rates of methodological errors calcu-
lated with MASTER.34 Furthermore, interpretative categories
may not be adjusted if the breakpoint is placed in a region of low
probability of target attainment as determined by Monte Carlo
simulations.
In conclusion, this study demonstrates how CBPs can be opti-
mized in a standardized process aiming to produce lower categor-
ization error rates. If the expected ME and VME rates using a single
CBP are not satisfactory, ZMUsmay be introduced in case an inter-
mediate zone is not appropriate (e.g. for pharmacokinetic/phar-
macodynamic reasons) and ME and VME rates cannot be
decreased by a change in the CBP.
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